A noninvasive treatment for knee arthritis has been developed that uses cooled radio energy to target and interrupt pain signals. Known as “Coolief,” the procedure can provide several months of relief from chronic arthritis pain for patients for whom surgery is not an option.
A pattern of genes has been identified that is characteristic of osteoarthritis and may be a step towards better treatments for this condition.
Scientists have uncovered a way to ‘program’ immune cells to cause less damage to the body, by tapping into a ‘broken’ chemical pathway in inflammation.
A possible link between type I interferons and a natural improvement of rheumatoid arthritis (RA) during pregnancy has been discovered by researchers. These findings could have significant implications in the development of safer therapies for RA.
In a recent study, individuals with rheumatoid arthritis who consumed fish twice weekly had lower disease activity (swollen/tender joint counts along with other assessments) than those who ate fish never to <1/month.
Gene mutations accumulating in cells are typical of the development of cancer. Researchers found that a similar accumulation of mutations occurs also in some patients with rheumatoid arthritis.
Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well. However, if they do not respond and no remission or at least reduction in the activity of the disease can be achieved, they are given a combined treatment of methotrexate and a biologic agent if risk factors are present. An international research group has now shown that there is another, equally effective oral treatment option.
In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement. The guidelines aim to reduce the risk of infection after joint replacement.
New research reveals promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA).
New research represents an important step towards characterizing the genetic basis of cardiovascular disease (CVD) risk in chronic immune-mediated inflammatory diseases (IMID).